Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma

Thumbnail Image
Download
Name

s41467-019-10307-9.pdf

Description
Published version
Size

1.82 MB

Format

Adobe PDF

Checksum (MD5)

0680eaa5f836906acb3ddb46e49f3803

sword-2020-02-04T16:02:36.original.xml (130 B)
Original SWORD entry document
Author(s)
Bandopadhayay, Pratiti
•
Piccioni, Federica
•
O’Rourke, Ryan
•
Ho, Patricia
•
Gonzalez, Elizabeth M.
•
Buchan, Graham
•
Qian, Kenin
•
Gionet, Gabrielle
•
Girard, Emily
•
Coxon, Margo
more
Date Issued
June 2019
Journal
Nature Communications
Publisher
Springer Science and Business Media LLC
Citation
Bandopadhayay, P. et al. "Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma." Nature Communications 10, 1 (June 2019): 2400 © 2019 The Author(s)
Version
Final published version
Abstract
BET-bromodomain inhibition (BETi) has shown pre-clinical promise for MYC-amplified medulloblastoma. However, the mechanisms for its action, and ultimately for resistance, have not been fully defined. Here, using a combination of expression profiling, genome-scale CRISPR/Cas9-mediated loss of function and ORF/cDNA driven rescue screens, and cell-based models of spontaneous resistance, we identify bHLH/homeobox transcription factors and cell-cycle regulators as key genes mediating BETi’s response and resistance. Cells that acquire drug tolerance exhibit a more neuronally differentiated cell-state and expression of lineage-specific bHLH/homeobox transcription factors. However, they do not terminally differentiate, maintain expression of CCND2, and continue to cycle through S-phase. Moreover, CDK4/CDK6 inhibition delays acquisition of resistance. Therefore, our data provide insights about the mechanisms underlying BETi effects and the appearance of resistance and support the therapeutic use of combined cell-cycle inhibitors with BETi in MYC-amplified medulloblastoma.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 4.0 International license
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/125375
DOI of Published Version
https://doi.org/10.1038/s41467-019-10307-9
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.